Study of brentuximab vedotin for relapsed hodgkin lymphoma
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a drug called brentuximab vedotin (BV) for people whose hodgkin lymphoma has come back or did not respond to earlier treatment. The goal is to see if BV can help control the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with classical hodgkin lymphoma (a type of lymphoma).
- Your cancer has come back (relapsed) or did not go away with treatment (refractory).
- You have received at least one treatment that included brentuximab vedotin (BV).
- You have a tumor that can be measured on a scan.
- You are 18 years old or older.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 trial studies brentuximab vedotin plus nivolumab in people whose classical Hodgkin lymphoma has come back or did not respond to treatment. It aims to shrink tumors and improve control of the disease, especially when standard options like transplant are not possible.
This study tests a treatment plan for adults with Hodgkin lymphoma that has returned or did not respond to ABVD chemotherapy. It may help people with a higher-risk pattern of disease, as long as their organ function and overall health meet study limits.
This study looks at how well brentuximab vedotin works for adults with Hodgkin’s lymphoma who have either already had, or are being considered for, stem cell transplant. It may help people who are receiving a specific treatment plan to control the lymphoma after transplant planning.
This Phase 2 study tests brentuximab and nivolumab (two anti-cancer medicines) in people with classical Hodgkin lymphoma that has come back or did not respond to earlier treatment. It may help by attacking lymphoma cells in different ways, especially after limited options from prior therapies.
This trial is a survey study that looks at how brentuximab vedotin is used in children with Hodgkin lymphoma. It focuses on people whose tumor is CD30-positive and who have not had prior treatment, to see how the drug fits with a standard chemotherapy plan (AVD).
This trial tests the drug brentuximab vedotin for children and young adults (ages 2 to under 35) who have just been diagnosed with classical Hodgkin lymphoma. The treatment is guided by PET/CT scans to see how well it works.
Hear when a new Hodgkin Lymphoma (Category) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.